As a consequence of confidentiality agreements, the identities from the trial participants remain undisclosed. Eli Lilly, the pharmaceutical business guiding retatrutide, declined to comment on the protocols of its ongoing trials but mentioned that client safety can be a priority.Retatrutide—the groundbreaking triple-action peptide revolutionizin